{"id":955584,"date":"2026-04-28T16:15:34","date_gmt":"2026-04-28T20:15:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/"},"modified":"2026-04-28T16:15:34","modified_gmt":"2026-04-28T20:15:34","slug":"caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/","title":{"rendered":"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing<\/b><\/p>\n<p><i>Transaction extends CareDx\u2019s Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM<\/i><\/p>\n<p><i>Estimated 2025 Revenue of $34 Million is expected to grow 30-40% annually for the next three years and neutral to CareDx\u2019s FY2026 Adjusted EBITDA guidance<\/i><\/p>\n<p>BRISBANE, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood\u2011based monitoring solution for viral\u2011mediated cancers. The transaction is an extension of CareDx\u2019s strategy to focus on its U.S. Precision Medicine Testing Services and Patient and Digital Solutions. The definitive agreement provides for an up-front cash consideration of $160 million with up to an additional $100 million based on the achievement of revenue milestones.<\/p>\n<p>\nNaveris\u2019 highly differentiated liquid biopsy platform is based on Tumor Tissue Modified Viral (TTMV\u00ae) DNA. The platform measures fragments of viral DNA released from tumor tissue into the bloodstream, serving as a highly accurate biomarker in human papillomavirus (HPV)\u2011driven cancers. This tumor\u2011na\u00efve testing is designed to support the management of patients from diagnosis through post\u2011treatment molecular residual disease (MRD) surveillance.<\/p>\n<p>\nNaveris reported unaudited revenue of $34 million in 2025, which we forecast to grow 30-40% annually for the next three years. For the first quarter of 2026, Naveris reported unaudited revenue of approximately $12 million, gross margins of 65% and net operating loss of $0.2 million. CareDx estimates the transaction will not impact its 2026 AEBITDA guidance and plans to provide further guidance following the close of the transaction.<\/p>\n<p>\n\u201cToday\u2019s announcement accelerates our growth strategy in Precision Medicine Testing Services and Patient &amp; Digital Solutions. We are focused on being a leader in concentrated specialty markets where a high burden of disease drives repeat testing. Naveris fits that profile with a differentiated technology that is early in its adoption,\u201d said John Hanna, President &amp; CEO of CareDx. \u201cNaveris is poised for strong growth, leveraging our core capabilities\u2014building belief in molecular testing, simplifying clinical workflow, and generating evidence for coverage and reimbursement.\u201d<\/p>\n<p>\nNaveris employs approximately 100 individuals and has performed more than 130,000 commercial tests to date. The test received Medicare coverage in 2023 and is a leading solution in Head &amp; Neck and Anal cancer MRD surveillance.<\/p>\n<p>\n\u201cNaveris has developed and commercialized a liquid biopsy monitoring platform proven to detect cancer earlier and with greater accuracy than conventional approaches,\u201d said James B. McNally, Chief Executive Officer of Naveris. \u201cWe are thrilled to be combining forces with CareDx to fulfill our mission of improving patient outcomes by delivering disruptive technology that transforms cancer care and expanding patient access to precision medicine.\u201d<\/p>\n<p>\nThe parties anticipate the transaction to close in the third quarter of 2026, subject to customary closing conditions.<\/p>\n<p>\nGoldman Sachs is acting as the exclusive financial advisor to CareDx in connection with the transaction. Fenwick &amp; West is acting as legal advisor to CareDx. J.P. Morgan Securities LLC is acting as the exclusive financial advisor to Naveris in connection with the transaction. Skadden, Arps, Slate, Meagher &amp; Flom LLP is acting as legal advisor to Naveris.<\/p>\n<p><b>About CareDx<\/b><\/p>\n<p>\nCareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company\u2019s integrated solutions include non\u2011invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics\u2011based information for transplant patients. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.caredx.com%2F&amp;esheet=54524785&amp;newsitemid=20260428112222&amp;lan=en-US&amp;anchor=www.caredx.com&amp;index=1&amp;md5=48a8ceeb5887d1eccba675405b51599d\">www.caredx.com<\/a>.<\/p>\n<p><b>About Naveris<\/b><\/p>\n<p>\nA portfolio company of B-FLEXION Life Sciences, Naveris is a privately held, commercial-stage precision oncology diagnostics company focused on improving outcomes for patients with viral-driven cancers. Founded in 2017, the Company develops and commercializes novel molecular diagnostics designed to enable earlier cancer detection and more personalized disease management. Naveris\u2019 proprietary NavDx\u00ae test is a clinically validated circulating tumor DNA blood test that detects tumor tissue\u2013modified viral (TTMV\u00ae) HPV DNA to support post-treatment surveillance and molecular residual disease (MRD) assessment in HPV-driven cancers. The Company operates high-complexity clinical laboratories in Massachusetts and North Carolina that are accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center and certified under CLIA. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnaveris.com%2F&amp;esheet=54524785&amp;newsitemid=20260428112222&amp;lan=en-US&amp;anchor=www.naveris.com&amp;index=2&amp;md5=7e68d949c3207b43bf904f63a0a8dad2\">www.naveris.com<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2F___http%3A%2Fwww.NavDx.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo1YzA1MzJmMmMwZGYyNTM5N2U0NGY4OTY0OTY2NTAwMjo2OmRkN2M6YmEyNWQ2MTQyYzJjZTgwMDE0NDE2NmZjZjYwMTBjYmQwOGRmYTE2MWMwZDRkMDliYjJlYjE5MjI3NzdiMjVhYTpwOlQ6Rg&amp;esheet=54524785&amp;newsitemid=20260428112222&amp;lan=en-US&amp;anchor=www.NavDx.com&amp;index=3&amp;md5=7c1c6554b1495a2b96bfb950ba3573d1\">www.NavDx.com<\/a>.<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nThis press release includes forward-looking statements related to CareDx including statements regarding the expected completion and timing of the acquisition, the anticipated impact of the transaction on CareDx\u2019s business, financial profile, and operating results, the benefits of the Naveris product, reimbursement coverage for the Naveris product, the achievement of CareDx\u2019s financial and operational goals and its expectations and prospects for 2026, the ability of CareDx to advance Naveris\u2019 platform technologies on a timely basis, if at all, the ability to satisfy all closing conditions and complete the transaction, difficulties or unanticipated expenses in connection with integrating the companies, and other statements that are not historical facts. These forward-looking statements are based on information currently available to CareDx and its current expectations, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the failure to obtain required regulatory approvals or satisfy closing conditions, delays in completing the transaction, general economic and market factors, and other risks discussed in CareDx\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these risks may cause CareDx\u2019s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx\u2019s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260428112222\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260428112222\/en\/<\/a><\/span><\/p>\n<p>\nCareDx, Inc.<br \/>\n<br \/>Media<br \/>\n<br \/>Natasha Moshirian Wagner<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:nwagner@CareDx.com\">nwagner@CareDx.com<\/a><\/p>\n<p>\nInvestor Relations<br \/>\n<br \/>Caroline Corner<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor@CareDx.com\">investor@CareDx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Surgery Infectious Diseases Genetics Health Technology Biotechnology Other Health Managed Care Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260428112222\/en\/2559419\/3\/CareDx_updated_logo_2025.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing Transaction extends CareDx\u2019s Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM Estimated 2025 Revenue of $34 Million is expected to grow 30-40% annually for the next three years and neutral to CareDx\u2019s FY2026 Adjusted EBITDA guidance BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211; CareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-955584","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing Transaction extends CareDx\u2019s Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM Estimated 2025 Revenue of $34 Million is expected to grow 30-40% annually for the next three years and neutral to CareDx\u2019s FY2026 Adjusted EBITDA guidance BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211; CareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated &hellip; Continue reading &quot;CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T20:15:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing\",\"datePublished\":\"2026-04-28T20:15:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/\"},\"wordCount\":1125,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/\",\"name\":\"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-04-28T20:15:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/","og_locale":"en_US","og_type":"article","og_title":"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing - Market Newsdesk","og_description":"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing Transaction extends CareDx\u2019s Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM Estimated 2025 Revenue of $34 Million is expected to grow 30-40% annually for the next three years and neutral to CareDx\u2019s FY2026 Adjusted EBITDA guidance BRISBANE, Calif.&#8211;(BUSINESS WIRE)&#8211; CareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated &hellip; Continue reading \"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-28T20:15:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing","datePublished":"2026-04-28T20:15:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/"},"wordCount":1125,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/","name":"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-04-28T20:15:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260428112222r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=955584"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/955584\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=955584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=955584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=955584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}